AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04150198 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TEP/IRM
Description: All participants will have a PET / MRI examination including: i) a 30-minute PET scan, 80 minutes after intravenous injection of 240 MBq of 18F-AV1451 ± 10% ii) a ZTE sequence (for attenuation correction of PET images), a 3D T1 anatomical sequence, a diffusion MRI, a functional MRI at rest (total duration: 45 minutes). These acquisitions will be made during the same exam session on a hybrid PET / MRI camera allowing simultaneous acquisitions. This visit lasts about 3 hours.
Study NCT04150198 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TEP/IRM
Description: All participants will have a PET / MRI examination including: i) a 30-minute PET scan, 80 minutes after intravenous injection of 240 MBq of 18F-AV1451 ± 10% ii) a ZTE sequence (for attenuation correction of PET images), a 3D T1 anatomical sequence, a diffusion MRI, a functional MRI at rest (total duration: 45 minutes). These acquisitions will be made during the same exam session on a hybrid PET / MRI camera allowing simultaneous acquisitions. This visit lasts about 3 hours.
Study NCT06052488 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strength After Breast Cancer
Description: Individual physical therapy evaluation and 4 group-based exercise sessions led by a licensed physical therapist
Study NCT04714970 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iTBS
Description: Intermittent theta burst stimulation (iTBS) on left dlPFC. 90% RMT, 50Hz within train and 5Hz train for 2 second and rest for 8 second. 600 train and 200 second in total.
Study NCT04714970 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Shame stimulation
Description: TMS coil vertical to the brain surface, with same protocol as iTBS
Study NCT06676371 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: E-vita® Open Neo; Artivion
Description: E-vita® Open Neo is a hybrid stent graft system for aortic arch and descending thoracic aorta repair with Frozen Elephant Trunk Technique.
Study NCT06676371 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoraflex Hybrid; Terumo
Description: The Thoraflex Hybrid is a device system designed to repair a weakened and bulging section (aneurysm) and/or a tear in the lining (dissection) of the aorta behind the heart (aortic arch). The system includes a polyester graft section that reinforces a weakened section of the blood vessel, a connected stented section (nitinol wire frame on polyester graft material) that holds the artery open, and a delivery catheter that is used to place the device. The polyester graft and stented sections are coated with a protein substance taken from animal body parts (gelatin) to seal the implant and prevent blood from leaking out.
Study NCT06676462 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Video laryngoscopy with visionPRO
Description: Video laryngoscopy to be performed using the visionPRO (HEINE® Optotechnick, Gilching, Germany) during intubation.
Study NCT06676462 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Video laryngoscopy with Glidescope
Description: Video laryngoscopy to be performed using theGlideScope (Verathon Inc., Bothell, USA) during intubation.
Study NCT05571722 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin Injection
Description: Patients receive a dose of 30 mg/kg of vancomycin (2 hours infusion) starting 2.5 hours before the scheduled time of surgical incision as defined in the French guidelines.
Study NCT05571722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid Injection
Description: Patients receive a dose of 1200 mg of linezolid (30 minutes infusion) 30 minutes before the scheduled time of surgical incision.
Study NCT04901741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaptesed pegol
Description: 400 mg per week as continous infusion until progression or intolerable toxicity
Study NCT04901741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg every 3 weeks as i.v. infusion until progression or intolerable toxicity or a maximum of 35 administrations
Study NCT06389188 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RHB Group
Description: The RHB-group were treated with passive manual therapy (P-MT) by soft tissue mobilization, massage and muscular stretching of the anterior and posterior cervical muscles; active therapeutic exercises (A-TE); and oculo-cervical exercises (OC-E). Patients received a total of 20 sessions of 30 minutes each during 4 weeks
Study NCT06389188 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RHB Group
Description: The RHB-group were treated with passive manual therapy (P-MT) by soft tissue mobilization, massage and muscular stretching of the anterior and posterior cervical muscles; active therapeutic exercises (A-TE); and oculo-cervical exercises (OC-E). Patients received a total of 20 sessions of 30 minutes each during 4 weeks
Study NCT05312424 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 300 mg olive oil
Study NCT05312424 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Low GG
Description: 150 mg GG
Study NCT05312424 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High GG
Description: 300 mg GG
Study NCT04976777 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Updated DEX PS DDS Applicator
Description: Intravitreal Administration
Study NCT04976777 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Approved DEX PS DDS Applicator
Description: Intravitreal administration
Study NCT06465732 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dupilumab
Description: the active comparator arm receive dupilumab only
Study NCT06465732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: the active comparator arm receive dupilumab only
Study NCT06465732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Description: the experimental arm receive dupilumab plus tofacitinib.
Study NCT04976777 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone 0.7 mg in a solid polymer drug delivery system
Study NCT04976777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 0.7 mg in a solid polymer drug delivery system
Study NCT06010680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]SHR2554
Description: Patients will receive single dose of orally \[14C\]SHR2554 on Day 1.
Study NCT04669249 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PROCare
Description: PROCare is a reward-based digital recovery management platform for individuals receiving medication treatment for opioid use disorder. Patients have the opportunity to earn both non-monetary and monetary incentives via smart debit card for a variety of clinically-indicated behaviors, including taking their medication (buprenorphine) as directed, attending clinic appointments and community-based mutual-help support group meetings, participating in routine outcomes monitoring surveys using validated measures, accessing the curated psychoeducation content library, and engaging in other recovery-oriented activities within the smartphone app.
Study NCT05883475 — intervention group
Intervention type: OTHER
Intervention: Disabilities of the Arm, Shoulder, and Hand Questionnaire
Description: Upper limb function was assessed with the Turkish version of the Disabilities of the Arm, Shoulder, and Hand Questionnaire (DASH). The questionnaire DASH is a self-report instrument with 30 items. The total score ranges from 0 to 100, with higher scores indicating a worse upper limb function.
Study NCT05883475 — intervention group
Intervention type: OTHER
Intervention: Arm Motor Ability Test
Description: The test assesses hemiparetic upper extremity functional tasks.The increase in the scores of both subparameters of the scale, which is composed of the parameters of functional ability and quality of movement, indicates an improvement in the motor functions of the upper limbs.
Study NCT05883475 — intervention group
Intervention type: OTHER
Intervention: Nine Hole Peg Test
Description: Fine motor skills of the upper extremities were assessed.The patient was asked to insert the nine sticks in the box on the table into the holes in the other box as quickly as possible and then remove them immediately. As time increases, fine motor skills of the upper extremities decrease
Study NCT05883475 — intervention group
Intervention type: OTHER
Intervention: Pittsburg Sleep Quality Index
Description: Sleep quality was assessed using the this test.This scale, which provides a quantitative measure of sleep quality, is a 19-item self-report scale. The total score greater than 5 indicates poor sleep quality.
Study NCT05883475 — intervention group
Intervention type: OTHER
Intervention: Functional Independence Measure
Description: This test assessed functional capacity in activities of daily living.The higher a person's score, the higher the level of independence.
Study NCT05707871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPECTRUM cigarettes
Description: SPECTRUM cigarettes have varying amount of nicotine content
Study NCT05707871 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: usual brand of Cigarettes
Description: Usual Brand of Cigarettes
Study NCT05857436 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: apical periodontitis
Description: Of these patients, 60 patients with AP and extraction indication (due to restorative causes and lesion size) were included in the study
Study NCT06475508 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Complarate®
Description: The investigational drug Complarate® was administered as an intravenous infusion at a dose of 8 mg/kg once every 4 weeks for 24 weeks.
Study NCT06475508 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Actemra®
Description: The reference drug Actemra® was administered as an intravenous infusion at a dose of 8 mg/kg once every 4 weeks for 24 weeks.
Study NCT05602402 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CAEP-01
Description: Dose: 1 capsule Route: orally for 84 ± 3 days Regimen: one capsule before breakfast (preferably with milk/butter/ghee)
Study NCT05602402 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dose: 1 capsule Route: orally for 84 ± 3 days Regimen: one capsule before breakfast (preferably with milk/butter/ghee)
Study NCT06125132 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Restoration with-tooth colored material
Description: Restoration of abrasions with different composite resin materials
Study NCT05814991 — intervention group
Intervention type: DRUG
Intervention: Nitroglycerin solution
Description: Controlled hypotension will be induced (intravenous administration of nitroglycerin 2-10 µg/kg/min) 15 minutes prior to the start of mucosal detachment, and will be sustained for the osteotomy stage.
Study NCT05814991 — intervention group
Intervention type: DEVICE
Intervention: monitoring of cerebral oxygen saturation
Description: NIRS-based monitoring of rSO2 has unique advantages: directly or indirectly detecting physiological changes and metabolic processes, it is easy to realize, and involves simple procedures.
Study NCT06233357 — intervention group
Intervention type: DRUG
Intervention: treated without (N), with casirivimab / imdevimab (C) or tocilizumab (T), solely, or in combination of both (C + T)
Description: IgG seronegative SARSCoV2-Spike antibody (\< 0,80 U/ml) COVID-19 patients were treated with 1 dose of subcutaneous casirivimab and imdevimab, 1200 mg (600 mg of each). Patients with CRP > 75 mg/l or IL-6 > 75 ng/l were treated with one dose of intravenous tocilizumab 8 mg/kg body weight
Study NCT05499039 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High flow nasal cannula (HFNC)
Description: High flow nasal cannula consists of an apparatus that allows adjustable FiO2 from 21 to 100% and delivers a modified gas flow up to 60 l/ min .~will be set with: -~Temperature at 37°C or 34°C Flow rate 30: 50 L/min. FiO2 will be adjusted to achieve a SpO2 at least 95%
Study NCT05499039 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-Invasive Mechanical Ventilation (NIV)
Description: Respiratory assistance is provided by a NIV either Puritan Bennet 840 , Engström Carestation or Hamilton-G5 , will be used for conventional non-invasive ventilation via an oronasal mask. Settings will be adjusted based on the clinical assessment of the respiratory therapist . Initial setting includes: -~Positive End Expiratory Pressure (PEEP): 5 cmH2O. Pressure support (PS): 12-20 cmH2O. FiO2 will be adjusted to achieve a SpO2 at least 95% Intervention: Device: non-invasive ventilation
Study NCT05775744 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tight postpartum blood pressure control
Description: The standard of care for patients with pregnancy induced hypertension is to start antihypertensive therapy if blood pressures are consistently over 150/100 mm Hg. There is no established standard of care for titrating blood pressure medication in the postpartum period for those with chronic hypertension and the approach to these patients varies by institution. The intervention in this study will be to start antihypertensive medications at a lower blood pressure cutoff, which is commonly used in the non-pregnant patient population to more tightly control blood pressure. Remote patient monitoring may be considered standard of care. The blood pressure targets chosen for this study are considered to be standard of care for non-pregnant people.
Study NCT06520319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-MGS5
Description: Each patient received a single intravenous injection of 68Ga-DOTATATE (2-4 mCi) and underwent PET/CT scanning 40-60 minutes after the injection. Or receive one intravenous injection of 68Ga-MGS5 and undergo two PET/CT scans at 1 and 2 hours post-injection, respectively.
Study NCT06107582 — intervention group
Intervention type: OTHER
Intervention: data collection
Description: The study will collect basic information, diagnostic and treatment information from medical records and use questionnaire to measure the exposure of patients, and prospectively follow-up to collect the prognosis information.
Study NCT04666506 — intervention group
Intervention type: OTHER
Intervention: Virtual reality
Description: The VR intervention, Relaxation-VR, is a VR application developed by Psylaris aiming to reduce anxiety/stress and pain by distracting the patient in a relaxing environment. Relaxation-VR will be administered via a commercially available VR headset (Oculus Go). The VR headset is a piece of equipment that a person wears over their eyes that allows them to experience images and sounds produced by a computer as if they were part of real life (Cambridge Dictionary, 2020). As such, the patient is immersed in a novel, calming and distracting environment where the he/she is asked to perform tasks that will help the patients to relax when distressed before and/or during a medical procedure or during their stay in hospital.~The Relaxation-VR application consists of three modules: two modules make use of relaxation principles (i.e. breathing exercises, meditation) and one module presents a scene with different interactive animations and objects (i.e. popping bubbles, playing fetch with a dog).
Study NCT04753580 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Stool collection
Description: The volunteer will receive the stool collection kit as well as the procedure to follow for this collection.~Treatment of stool after collection:~The stool will be treated according to the following two procedures:~i) part of the stool will be sequenced and will be stored as quickly as possible (4 hours maximum) at -80 ° C, 3 separate aliquots of 1 g; ii) the other part will be intended for implantation in rats and must be homogenized in a final concentration of 20% glycerol (2 hours maximum) and then stored at -80 ° C, 3 aliquots of 1 g.
Study NCT05433935 — intervention group
Intervention type: OTHER
Intervention: Observation
Description: This is an observational study.
Study NCT05254769 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neurofeedback Equipment (Cygnet) by BEE Medic GmbH Technologies, Baden-Wurttemberg, Germany.
Description: The EEG NeuroAmp (Electroencephalogram Amplifier) is a user-friendly high-performance interface between client and clinician computer. It can be used in two different functionalities: In an EEG/ERP (Event related potential) measurement and in an EEG biofeedback (neurofeedback) and/or peripheral biofeedback setting.
Study NCT05495477 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EIT
Description: Evaluation of ventilation distrinution during deep sedation through EIT
Study NCT06149182 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Life stress interview according to EAET
Description: This interview has the aim to jointly explore potential emotional factors contributing to patients functional somatic symptoms. While exploring this, it has the aim to not only describe such potential patterns but also emotionally process them.
Study NCT06149182 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychiatric interview according to region stockholm - basutredning
Description: This interview has the aim to gain enough information to diagnose some of the main psychiatric disorders
Study NCT05111067 — intervention group
Intervention type: GENETIC
Intervention: DNA and whole transcriptome mRNA sequencing
Description: DNA and whole transcriptome mRNA sequencing, including total mutational burden and microsatellite instability, will be performed using the TruSight Oncology 500 (TSO500) platform (Illumina Canada, Ulc).
Study NCT05041829 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary sodium
Description: Low sodium diet with sodium of \<2.3 g/day (\<100 mmol/day) and high sodium diet with sodium of ≥4 - \<6 g/day (≥174 - \<261 mmo/day)
Study NCT05041829 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary sodium
Description: Low sodium diet with sodium of \<2.3 g/day (\<100 mmol/day) and high sodium diet with sodium of ≥4 - \<6 g/day (≥174 - \<261 mmo/day)
Study NCT06489925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cerebrolysin
Description: The Cerebrolysin will be administered at least one hour after the standard treatment and no later than 24 hours after the stroke symptom onset.
Study NCT05313490 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Beetroot Juice
Description: 7 days of 140 mL per day of beetroot juice
Study NCT05313490 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Beetroot Juice
Description: 7 days of 140 mL per day of placebo beetroot juice
Study NCT06206590 — intervention group
Intervention type: OTHER
Intervention: Whole-proteomic assay
Description: Whole-proteomic analysis was performed on all the blood samples
Study NCT03956160 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A co-design phase aims to ensure the feasibility and relevance of the proposed intervention and evaluation.
Description: 4 participatory co-design workshops lasting 4 hours each that will follow a user-centered design approach: identification of end-user needs, prototyping/development of the intervention (case-management procedures and platform), iterative improvement, end-user testing.~Based on the cognitive social theory underpinning the intervention, scientific literature, an overview of existing organizations and the results of the Stroke 69 and Arthur Tybra studies (patient needs following the acute phase), the advisory committee will:~* Define the case-manager's profile, and required knowledge and skills~* Identify the resources and tools to be proposed on the Internet platform~* Test the tools and content~* Refine the program evaluation criteria~* Test and validate the study procedures.
Study NCT06169046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clenbuterol
Description: tablets
Study NCT06169046 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: tablets
Study NCT06460389 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Visual Acuity Assessment
Description: Uncorrected visual acuity for nine distances (25, 28, 33, 40, 50, 60, 100, 200, 300 cm) examination via a Democritus Digital Acuity \& Reading Test (DDART).
Study NCT06448598 — intervention group
Intervention type: OTHER
Intervention: Exercise
Description: The exercise protocol involved twice-weekly sessions, with aerobic exercises performed at 70% of the maximum heart rate achieved during the step test, and resistance exercises at 60% of 1RM. Participants self-selected their exercise timing, either intradialytic (during HDF sessions) or interdialytic (on non-dialysis days). For the intradialytic group, exercise was seamlessly integrated into the HDF session, excluding the initial and final two hours of dialysis.
Study NCT06376383 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tonsillectomy
Description: Standard tonsillectomy
Study NCT06376383 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tonsillotomy
Description: Tonsillotomy
Study NCT05795114 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reach Out, Stand Strong, Essentials for New Mothers (ROSE) Program
Description: A 5-part interpersonal therapy based intervention
Study NCT06348407 — intervention group
Intervention type: DRUG
Intervention: IgE monoclonal antibody
Description: omalizumab
Study NCT06357104 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electroencephalogram biofeedback
Description: EB is conducted for 20 minutes per section with two sections per day in the primary efficacy endpoint.
Study NCT06357104 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electrical brain stimulation
Description: EBS is conducted for 20 minutes per section per day in the primary efficacy endpoint.
Study NCT06357104 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultra-low frequency transcranial magnetic stimulation
Description: ULF-TMS is conducted mainly for the left side of the participant's brain for 20 minutes per section per day in the primary efficacy endpoint.